Eloralintide is an amylin receptor agonist — the same family as cagrilintide. Amylin is a natural hormone your body releases alongside insulin that signals to your brain, "I'm full." These drugs amplify that signal: more satiety, slower gastric emptying, and less food intake. The amylin space is heating up fast, and this is shaping up to be a serious next-wave player alongside the GLP-1s. So if you already understand cagrilintide, you understand the basics here. Same hormone pathway, same once-weekly injection, same goal. ————————————— 🆚 HOW IT'S DIFFERENT FROM CAGRILINTIDE Although Similar, the two drugs take opposite design approaches: Cagrilintide = NON-selective. It activates multiple amylin and calcitonin receptors. Eloralintide = SELECTIVE. It targets one specific receptor (AMY1R) — the theory being a cleaner, more targeted effect with fewer off-target reactions. In animal studies, that selectivity translated to LESS nausea and taste-aversion than cagrilintide. The holy grail in this space: strong results with easier tolerability. And the head-to-head monotherapy weight-loss numbers? Eloralintide came out ahead: ➡️ Eloralintide (top doses): up to ~20% weight loss at 48 weeks ➡️ Cagrilintide (2.4mg solo): ~11.8% weight loss at 68 weeks That's nearly DOUBLE the weight loss — in less time. (Worth noting: these are separate trials, so it's not a perfect apples-to-apples, but the gap is striking.) ————————————— 📊 THE STATS THAT STAND OUT ➡️ Dose-dependent weight loss: ~9% (1mg) climbing to ~20% (9mg), versus just 0.4% on placebo ➡️ Weight loss had NOT plateaued at 48 weeks — meaning the true ceiling could be even higher ➡️ 81–92% of people in the higher-dose groups lost 10% or more of their body weight ➡️ Waist circumference dropped up to ~17 cm — that's 6–7 inches, or several belt holes ➡️ Most of the weight lost was FAT, not muscle (confirmed by DEXA scans) ➡️ Bonus wins: improved cholesterol and A1c, plus up to a 64% drop in hsCRP (a key inflammation marker)